TradeFlare's AI research teams analysed CLOV on 8 market nights between May 11, 2026 and September 16, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 16, 2026 | HOLD | $4.66 | — / — | +0.2% | not yet | Clover Health achieved GAAP net income profitability in Q2 2026 with positive forward EPS and raised guidance. |
| September 15, 2026 | HOLD | $5.10 | — / — | +0.2% | +3.2% | Mandatory trading rules prevent an actionable BUY recommendation at the current price. |
| July 14, 2026 | BUY | $4.57 | — / — | -0.6% | -8.9% | Potential for a short-term oversold bounce given the RSI pullback signal. |
| July 13, 2026 | BUY | $4.44 | — / — | -1.5% | +0.0% | The scanner triggered a mean-reversion signal, but the overall team sentiment and risk profile do not support a buy. |
| July 10, 2026 | BUY | $4.68 | — / — | +4.0% | +7.2% | The current setup does not meet the criteria for a buy. |
| July 9, 2026 | BUY | $4.66 | — / — | -6.0% | -0.4% | The current market regime and the stock's internal metrics do not support a new trade. |
| May 12, 2026 | HOLD | $3.20 | — / — | +6.7% | +49.1% | Continued positive momentum from the EPS beat and PEAD signal. |
| May 11, 2026 | BUY | $3.12 | $3.74 / $2.65 | +5.9% | +34.1% | The current market regime and the stock's technical and fundamental profile do not support a confident entry at this time. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.